Knowing stock market today at a glance

Why Did Mineralys Shares Plunge 11.33%? Goldman Sachs Cuts Target

Mover TrackerThursday, May 1, 2025 5:42 am ET

1min read

On May 1, 2025, mineralys shares plummeted by 11.33% in pre-market trading, marking a significant downturn for the company.

Goldman Sachs recently adjusted its price target for mineralys therapeutics, reducing it from $28.00 to $24.00 while maintaining a "buy" rating. This revision reflects the firm's updated outlook on the company's prospects, which may have contributed to the recent decline in share price.

Additionally, Boothbay Fund Management LLC acquired 44,067 shares of Mineralys Therapeutics, indicating continued interest from institutional investors despite the recent price drop. This acquisition suggests that some investors remain optimistic about the company's long-term potential.

Mineralys Therapeutics has experienced a range of share prices over the past year, with a fifty-two week low of $8.24 and a fifty-two week high of $18.38. This volatility underscores the challenges and opportunities facing the company as it navigates the competitive landscape of the biotechnology sector.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.